Single answer
Is Axcella Health Inc (AXLA) a buy or sell?
4starter turns market data into one clear verdict you can act on.
Create a free account to save tickers and track your signals.
Log in to turn on watchlist alerts.
What is the conclusion?
Right now our advanced algorithms say:
Do analysts agree?
We compare consensus targets with today's price.
Consensus target for Axcella Health Inc is $60.00, which is $55.42 (1,210.04%) above the current price today's price.
Low target: $60.00 | High target: $60.00
Company snapshot
A quick overview of the business and its public profile.
Axcella Health Inc operates as a clinical stage biotechnology company in the United States The company treats complex diseases and enhances health using endogenous metabolic modulator compositions Its lead product candidates include AXA1665 which is in Phase 2 clinical trial for the reduction in risk of overt hepatic encephalopathy recurrence and AXA1125 that is in Phase 2b clinical trial for treating nonalcoholic steatohepatitis as well as in Phase 2a clinical trial for Long COVID therapy for patients The company was formerly known as Newco LS16 Inc and changed its name to Axcella Health Inc in June 2016 Axcella Health Inc was incorporated in 2008 and is based in Cambridge Massachusetts
Website: httpswwwaxcellahealthcom
Rates and inflation backdrop
US inflation for September 2025 was 0.31%. Over the last 12 months, inflation is 3.02%. The 10-year yield is 4.12 and is down -0.1000 over the last 30 days.
Inflation sensitivity
Debt ratio: 0.11. Cash flow to debt ratio: -32.20. Net profit margin: 0.00%. Inflation risk score: high (0.75/1).
Dividend history check
We cannot find any recorded dividends paid in our systems.
Trading liquidity
Yes, the average daily trading liquidity for Axcella Health Inc is $9.3M. You should therefore be able to get in and out of your positions relatively fast.
10-year return check
We cannot find data for Axcella Health Inc 10 years ago, but if you had invested on 2019-05-09 when the price was $345.00, you would have made a loss of $340.42 per share or 98.67%.
Why this answer
We combine price momentum, volatility, and trend signals to simplify the decision to one word.
Signal engine scans price, trend, and momentum indicators.
Targets and sentiment are checked against the live quote.
We keep the output simple: buy, sell, or hold.
Analyst consensus
How Wall Street targets compare to today's price.